Omeros Corp. shares surged 15% in midday trading on Tuesday after the U.S. Food and Drug Administration issued a routine update indicating no new issues with the company's experimental drug OMS721.
The FDA’s Type A meeting minutes, released after the close of markets on Monday, confirmed that regulators had no additional questions or concerns regarding the Biologics License Application for OMS721, a treatment for atypical hemolytic uremic syndrome and other complement-mediated disorders. The update follows a recent Type B meeting where the agency sought clarification on manufacturing and clinical data.
Analysts noted the FDA’s latest communication as a positive signal, reducing uncertainty around the drug’s approval timeline. Omeros, a Seattle-based biopharmaceutical company, has faced delays in the approval process, with the FDA previously requesting additional information in March. The company had stated that it believed it had addressed all outstanding questions at that time.
The stock’s gain marked a reversal from recent declines, with Omeros shares down roughly 20% over the past month amid regulatory uncertainty. The surge added to a volatile stretch for biotech equities, where sentiment often hinges on FDA communications.
Omeros did not immediately respond to requests for comment. The FDA’s next steps remain contingent on its ongoing review, with no formal decision date set for the Biologics License Application.
